The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 151 results:
Author [ Title(Desc)] Type Year
Filters: Author is Mikhailidis, Dimitri P  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial.. J Hepatol. 57(2), 476.
Karagiannis, A., Tziomalos K., Papageorgiou A., Kakafika A. I., Pagourelias E. D., Anagnostis P., et al. (2008).  Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.. Expert Opin Pharmacother. 9(4), 509-15.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Stage of chronic kidney disease and severity of coronary heart disease manifestation.. Expert Opin Pharmacother. 13(4), 457-60.
Athyros, V. G., Tziomalos K., Florentin M., Karagiannis A., & Mikhailidis D. P. (2010).  Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. Curr Med Res Opin. 26(4), 839-42.
Katsiki, N., Athyros V. G., & Mikhailidis D. P. (2015).  Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly.. Atherosclerosis. 238(2), 182-4.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Statin-fibrate combination for mixed dyslipidaemia: a limited option?. Curr Med Res Opin. 26(9), 2137-40.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Pagourelias E. D., Savvatianos S. D., Elisaf M., et al. (2007).  Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients.. Open Cardiovasc Med J. 1, 8-14.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.. Curr Vasc Pharmacol. 7(3), 264-6.
Athyros, V. G., Karagiannis A., & Mikhailidis D. P. (2010).  Statins and heart failure.. J Am Coll Cardiol. 55(15), 1644-5; author reply 1646.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Statins and nonalcoholic fatty liver disease: a bright future?. Expert Opin Investig Drugs. 22(9), 1089-93.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and non-alcoholic steatohepatitis.. J Hepatol. 64(1), 241-2.
Athyros, V. G., Kakafika A., Karagiannis A., & Mikhailidis D. P. (2007).  Statins and regression of coronary atherosclerosis.. JAMA. 297(20), 2197; author reply 2197.
Athyros, V. G., Karagiannis A., Kakafika A., Elisaf M., & Mikhailidis D. P. (2007).  Statins and renal function. Is the compound and dose making a difference?. Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and Type 2 Diabetes Mellitus: An Update After 1 Year.. Curr Pharm Des. 22(18), 2723-5.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opin Pharmacother. 16(10), 1449-61.
Paraskevas, K. I., Athyros V. G., Briana D. D., Kakafika A. I., Karagiannis A., & Mikhailidis D. P. (2007).  Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures.. Curr Drug Targets. 8(8), 942-51.
Anagnostis, P., Karras S. N., Athyros V. G., Mikhailidis D. P., & Karagiannis A. (2014).  Subclinical Cushing's syndrome and cardiovascular disease.. Lancet Diabetes Endocrinol. 2(5), 361.
T
Athyros, V. G., Mikhailidis D. P., Papageorgiou A. A., Didangelos T. P., Peletidou A., Kleta D., et al. (2005).  Targeting vascular risk in patients with metabolic syndrome but without diabetes.. Metabolism. 54(8), 1065-74.
Kostapanos, M. S., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Therapeutic options for statin-intolerant patients.. Curr Med Res Opin. 28(3), 345-9.
Athyros, V. G., & Mikhailidis D. P. (2014).  Therapy: Caloric and fat intake in statin users.. Nat Rev Endocrinol. 10(8), 450-1.
Athyros, V. G., Gossios T. D., Tziomalos K., Florentin M., Karagiannis A., & Mikhailidis D. P. (2011).  Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. Arch Med Sci. 7(6), 1067-75.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  To switch (statins) or not to switch? That is the question.. Expert Opin Pharmacother. 11(18), 2943-6.
Tziomalos, K., Athyros V. G., Karagiannis A., Kolovou G. D., & Mikhailidis D. P. (2009).  Triglycerides and vascular risk: insights from epidemiological data and interventional studies.. Curr Drug Targets. 10(4), 320-7.
U
Athyros, V. G., & Mikhailidis D. P. (2014).  Uric acid, chronic kidney disease and type 2 diabetes: a cluster of vascular risk factors.. J Diabetes Complications. 28(2), 122-3.
Athyros, V. G., Alexandrides T. K., Bilianou H., Cholongitas E., Doumas M., Ganotakis E. S., et al. (2017).  The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.. Metabolism. 71, 17-32.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.